BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Really Lead to Longevity Leaps? Text: @OncoAlert @oncology @BreastCancerNow @SABCS @ProfMatteoLambertini #SABCS24…
Browsing: Breast
Breast Cancer
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results Text Version: @DFCI_BreastOnc @Otto_DFCI @OncoAlert @PfizerIbrance @pfizer_news @SABCSSanAntonio @AACR #SABCS24…
We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.
“So basically, we looked at two factors, the one saying the long term remission of heart positive metastatic breast cancer…
In his analysis, Paolo Tarantino, MD, delves into the transformative potential of CDK4/6 inhibitors in breast cancer therapy. He questions whether these drugs, celebrated for their promise in clinical trials, have truly matched expectations in real-world scenarios, specifically referencing data from the NATALEE and monarchE trials. The discussion is visually represented by a superhero figure donning a CDK4/6 emblem, symbolizing the hope and power these inhibitors bring to the fight against breast cancer. This image captures the essence of current medical debates surrounding the efficacy and application of these treatments in managing breast cancer recurrence and overall patient outcomes.
The ZEST trial marks a pivotal moment in oncology, focusing on circulating tumor DNA (ctDNA) surveillance to detect molecular residual disease in breast cancer patients. This study explored whether Niraparib, a PARP inhibitor, could extend disease-free survival in patients with detectable ctDNA post-treatment but without visible signs of recurrence. The findings offer insights into both the potential and the limitations of using ctDNA for personalized cancer management.
The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study, examining the efficacy of ENHERTU®…
EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer Treatment The results of the Phase 3 EMBER-3 trial were unveiled at…
The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage…
Dr. Nathalie M. Johnson, MD, a breast cancer specialist with Legacy Health Partners, delves into the evolving role of circulating…
Introduction Dr. Kevin Hughes, MD, from MUSC Health, sheds light on a critical issue in the field of oncology: the…
Genetic Testing Cancer In recent years, the field of oncology has witnessed significant advancements, particularly in the realm of genetic…
In the evolving landscape of cancer treatment, ctDNA (circulating tumor DNA) testing has emerged as a pivotal tool in managing…
Author: Dr. Alexis LeVee, City of Hope At the ASCO 2024 conference, Dr. Alexis LeVee from City of Hope presented…
Introduction The recent findings from the DESTINY-Breast06 Phase III trial signify a potential shift in the treatment landscape for HR-positive,…
… [VIDEO with 39 SLIDES] – Dr. Rebecca Shatsky, MD from the 2024 MOASC Annual Oncology Summit & Research Symposium…
Wassim Mchayleh, MD, a speaker at the Medical Data and Analysis Symposium (MDAS), discusses the integration of circulating tumor DNA…
By. Halle Moore, MD Date. 12/13/2023 Halle Moore, MD, the Medical Doctor and Director of Breast Medical Oncology and Co-Director…
Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a medical oncologist from the University…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with Thomas Budd, MD, a medical…
Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr. Adam Brufsky, a medical doctor,…
Wassim Mchayleh, MD, an expert in oncology, participated in the SABCS 2023 conference, offering insights into the latest developments in…
Allen Wilbanks stood alongside Alina Hamilton, PhD, at the SABCS 2023 event, where they delved into groundbreaking research on breast…
By: Melinda Telli, MD, Date: 12/9/2023 At the SABCS 2023 conference, we had the privilege of interviewing Melinda Telli, MD,…
By: Hope Rugo, MD Date: 12/9/2023 At the SABCS 2023 conference, medical oncologist Hope Rugo from the University of California,…
By: Yara Abdou, MD, Date. 12/08/2023 At SABCS 2023, Yara Abdou, MD, a medical oncologist from the University of North…
By: Hatem Azim, MD Date. 12/08/2023At SABCS 2023, a discussion on fertility preservation and assisted reproductive technologies in breast cancer patients…
Treatment differences by race and age in metastatic hormone receptor-positive/HER2- with Yara Abdour, MDTranscript (spelling not corrected)Yara Abdou, MD -…
By: Julie Lang, MD Date. 12/07/2023Julie Lang, MD, a medical professional known for expertise in breast cancer research, has developed…
By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist Terry Mamounas, MD, the NSABP…
By. Kellogg Parsons, MD Date: 12/07/2023 Kellogg Parsons, MD, a medical doctor and Vice President of Clinical Development at Embrace Therapeutics,…
By. Ruth O’Regan MD Date: 12/07/2023In an interview, Ruth O’Regan MD addresses questions related to the use of CDK4/6 inhibitors in…
By. Neil Carleton, MD Date. 12/07/2023 In the interview with Neil Carleton, MD, the discussion revolved around the age-related remodeling of…
By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast cancer research and prevention, will…
By: Joyti Bajpai, MD Date: 12/07/2023 In a forthcoming interview, Jyoti Bajpai, MD, a renowned expert in the field, will…
By. Peter Schmid, FRCP, MD, PhD Date. 10/11/2023 KEYNOTE-522 Phase 3 Results – Was Pembrolizumab a Win in Triple-Negative Breast…
By. Stuart McIntosh, MDDate. November 03, 2023Stuart McIntosh, MD, Chief Medical Officer, initiated a study in the field of oncology.…
By. Aditya Bardia, MDDate. November 01, 2023 Dr. Aditya Bardia, an oncologist specializing in breast cancer treatment, provided insights into…
In a recent interview, Peter Fasching, MD, Professor of Women’s Cancer Specialist at the University Hospital in Erlangen, Germany, discussed…
Sayeh Lavasani, MD of UCI Health gives an Update in Breast Cancer at MOASC’s Spotlight on Oncology NATALEE’s study focused…
Dr. Sayeh Lavasani, MD, MSc, FRCPC, an Associate Clinical Professor in the Division of Hematology Oncology at the Department of…
Breast cancer is a topic that has garnered significant attention over the years, and for good reason. Affecting millions worldwide,…
Virginia Kaklamani, MD – UT Health San Antonio discusses Elacestrant (ORSERDU), an oral endocrine therapy, has been approved by the…
KEY TAKEAWAYS: Ribociclib, a CDK4/6 inhibitor, is a promising drug in the treatment of early-stage and metastatic breast cancer, particularly…
TROPiCS-02 Trial: The TROPiCS-02 trial showcases the potential of Sacituzumab Govitecan, a Trop-2 directed antibody-drug conjugate, as a promising treatment…
Abemaciclib, a CDK4 & 6 inhibitor, has shown a sustained benefit in invasive disease-free survival in high-risk EBC, as seen…
Constantinos Savva, MD, M.Sc., PGDip, MRCP, SCE, from the University of Southampton conducted a study on the effects of metformin,…
Erika Hamilton, MD, a preeminent expert from the Sarah Cannon Research Institute, has recently conducted a study evaluating the efficacy…
Nadia Harbeck, MD, PhD, from the University of Münster, recently conducted a primary outcome analysis of the multicenter randomized PreCycle…
Ian Krop, MD, PhD – Yale University This study conducted an age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients…